Benzinga | Nov 12, 2021 06:11AM EST

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Raises Price Target to $14

HC Wainwright & Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:APTO) with a Buy and raises the price target from $9 to $14.